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Abstract
Eighteen international cancer centres responded to a questionnaire designed to determine clinic practices regarding
the management of Hereditary Non-Polyposis Colorectal Cancer (HNPCC). Areas covered include definition,
clinical intakes, pre-genetic testing for microsatellite instability (MSI) or expression of mismatch repair (MMR) genes
by immunohistochemistry (IHC), mutational analysis, consent practices, counselling, surveillance planning, and
surgical decision making. In the absence of a firm evidence base, some management practices were variable, with
local access to funding and other resources being influential. More consistent responses were evident for management
practices with a stronger evidence base from previous clinical research. This document provides important information
to guide the management of HNPCC patients, allow comparisons to be made between the approaches of various
clinics to HNPCC families, and define management issues that need to be addressed in clinical research. 
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Introduction
HNPCC is an autosomal dominant condition with
high penetrance for colorectal and certain other cancers.
A mutation in one of the several mismatch repair genes
is responsible. Mutational analysis is widely available to
guide risk assessment and screening strategies in families
with HNPCC. However, there are many management
decisions that need to be made where the level of
evidence supporting those decisions is low. In September
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2003, participants at the International Collaborative
Group for Hereditary Non-Polyposis Colorectal Cancer
were invited to complete a questionnaire relating to their
clinic practices, so as to inform the cancer genetics
community about variations and levels of consensus. 
Methods
Eighteen centres (three from Australia, nine from the
UK, two from the USA, two from Denmark, one from
Canada, one from Israel) responded to the questionnaire.
The questionnaire covered clinical definitions of HNPCC
and high and moderate risk, thresholds for referral to
clinics, positioning and funding of pre-genetic testing in
clinical management, indications and funding for
mutational analysis, consent protocols, counselling
relating to variants of uncertain significance, disclosure
of genetic testing information across families, surveillance
planning for colorectal, gynaecological and other
malignancies, and surgical decision making. Responses
were generally in the multiple choice format, and where
appropriate one or more “correct” answers were allowed.
Free text provision (“other”) was liberally provided
throughout. The questionnaire was not anonymous.
However, as there was no universal agreement from the
contributors to identify their own familial clinic's response,
the results are presented anonymously. 
Results
Results are displayed with reference to the question
and the multiple choice response alternatives. 
A. Definition
1. In your familial bowel cancer practice, for the
purposes of initiating direct mutational analysis
(without necessarily requiring evidence of MSI/IHC
MMR protein loss), which definition of HNPCC do
you accept? (tick any) 
a) Amsterdam I
b) Amsterdam II
c) Amsterdam II plus ovarian cancer
d) Amsterdam II plus stomach cancer
e) Amsterdam II plus biliary tract cancer
f) Amsterdam II plus brain cancer
g) Amsterdam II plus breast cancer in hMLH1
h) Amsterdam II plus clear cell cancer of kidney
i) Other---please specify any variation
All but two centres allow direct progression to
germline testing in families meeting Amsterdam I (n=15)
and/or Amsterdam II (n=16) criteria. In one of the two
exceptions, germline testing proceeds only after IHC/MSI
is done, and in the other no germline testing is offered.
For the purposes of direct mutational analysis, 11 centres
accepted ovarian cancer as an HNPCC-defining
characteristic, 13 centres accepted stomach cancer, 10
centres accepted biliary cancer, 9 accepted brain cancer
(one specified glioblastoma only), 5 centres accepted
breast cancer in hMLH1 families, 8 centres accepted
clear cell cancer of the kidney and one centre would
accept direct germline testing in very early onset HNPCC
cancers regardless of family history. Family size influenced
one centre (more likely to test if family size small). 
B. Clinical Intakes
1. How do you define high/moderate risk? 
a) as above, 
b) others – specify. 
Six centres define high risk according to Amsterdam
II Criteria with variable acceptance of extracolonic cancers
as per their response to the definition question above.
Australian centres define risks as per Australian Cancer
Network Guidelines (see Table 1). A European centre
defines high risk as Amsterdam I/II, risk causing mutations
found, significant abnormal IHC/MSI, or suspicious family
history. This centre also defines moderate risk as “late
onset HNPCC” (three 1st degree relatives CRC>50 yrs),
or “young relative” (one 1st degree relative CRC<50
yrs). Another European centre defines high risk as
Amsterdam positive and moderate risk as three 1st degree
relatives CRC>50 yrs, or two 1st degree relatives
CRC<50 yrs. A British centre defines moderate risk as
one relative under 45, or two relatives under 70. Another
British centre includes MSI-H status in risk assessment and
families with two relatives affected as moderate risk. The
remaining other centres have their own guidelines. 
2. Does your clinic accept intakes 
a) high risk only
b) moderate and high risk
c) selected moderate risk plus high risk
d) no discrimination, accept referral on demand
e) others
No clinics accepted only high-risk families for
counselling. Six centres accepted all high and moderate
risk patients and families. Five accepted high risk and
selected moderate risk and four had an open referral
policy, with one accepting all, but encouraging moderate
and high-risk referrals. One British clinic triaged
consultative attendance after receiving a response from
a family history questionnaire. One US clinic had specific
guidelines not captured by the questionnaire. 
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Table 1. ACN Guidelines
The Australian Cancer Network (2002) has developed guidelines for categorizing families, and recommends referral of families 
for consideration of risk assessment and pre-genetic or genetic testing to familial cancer services. 
Suggested Definition of “Potentially High Risk”: 
• Three or more first- or second-degree relatives on the same side of the family are diagnosed with bowel cancer. 
• Two or more first- or second-degree relatives on the same side of the family are diagnosed with bowel cancer plus any of the following
high risk features: 
– multiple bowel cancers in a family member, 
– bowel cancer before age 50 years, 
– a family member who has/had an HNPCC-related cancer (endometrial, ovarian, stomach, small bowel, renal pelvis or ureter, biliary tract,
brain cancer)*
• at least one first- or second-degree relative diagnosed with bowel cancer with a large number of synchronous adenomas (suspected FAP),
• there is a member of the family in which a gene mutation that confers a high risk of bowel cancer has been identified. 
*The Australian Cancer Network guidelines extend the range of cancers implicated in HNPCC based on subsequent literature identifying other cancers in the syndrome.
Additional tumours for consideration: Breast in hMLH1 families [1], clear cell kidney [2]. 
Suggested Definition of “Moderately Increased Risk”: 
• One first-degree relative with bowel cancer diagnosed before age 55 years (without potentially high-risk features).
• Two first- or second-degree relatives on the same side of the family with bowel cancer diagnosed at any age (without potentially high-risk
features). 
C. Pre-Genetic Testing
1. Does your clinic offer 
a) MSI testing and IHC for MMR protein loss
together, 
b) IHC for MMR protein loss first, and MSI if the
IHC is negative, 
c) IHC of MMR proteins first and MSI if specifically
requested for particular reasons, 
d) IHC for MMR protein loss only, 
e) MSI only, 
f) other strategies – specify. 
Eleven centres representing all continents test for
MSI and IHC together. One British centre did IHC first,
and then MSI if IHC is negative, and three others add
MSI on specific clinical indication. Two centres offered
only IHC. No centres offered only MSI. One British
centre did MSI first, followed by IHC if positive and one
centre offered neither. 
2. Do you gain consent for MSI testing
a) always, 
b) only when the information is to be used for
familial risk purposes, 
c) never or rarely because, for example, we see it
as a test aiding specific patient management with
minimal familial implications requiring consent, 
d) sometimes or never because_ _ _ _ _, 
e) with other restrictions (please specify). 
3. Do you gain consent for IHC for MMR proteins
a) always, 
b) only when the information is to be used for
familial risk purposes, 
c) never or rarely because, for example, we see it
as a test aiding specific patient management with
minimal familial implications requiring consent, 
d) sometimes or never because_ _ _ _ _, 
e) with other restrictions (please specify). 
Consent was secured for, respectively, MSI and IHC
testing always (11, 13 responders), only when informing
familial risk (2, 3 responders), never or rarely 
(1, 2 responders), differentially according to whether
initiated by the genetic department or pathology
department (1, 0 responders). Some centres did not
respond to the question (3, 1 responders) including one
where testing was unavailable. 
4. Do you restrict MSI and/or IHC strictly to individuals
meeting Bethesda criteria? If not, please indicate
principles you follow in that variation – either in being
more restrictive or less restrictive. Please provide
evidence for variation if available. 
Nine centres restrict MSI and/or IHC to individuals
meeting Bethesda criteria. The less restrictive practices
beyond Bethesda criteria were as follows: for research
purposes, older age multi-case families, on patient
request. One British centre proceeded with testing if
tumour specimens are available in the family, with
a view to defining non-MMR families for research
purposes. An Australian centre included multiple-case
families without young age of onset. One US centre
tested also on patient request. Some centres were
more restrictive than the Bethesda Criteria including
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families meeting only Amsterdam Criteria (n=1), or
used the Wijnen model for prediction of MMR [3]
(n=1). A US clinic reported its own specific criteria.
Two British centres did not respond. 
5. Do you think the Bethesda criteria are inadequate
for deciding on pre-genetic testing? If so, why?
Seven centres felt that the Bethesda criteria were
adequate. Six centres considered the Bethesda
criteria were too complex and lacked specificity. Five
centres do not use the criteria. 
6. Who pays for MSI testing in your practice? (tick one
or more) 
a) the public health system, 
b) the patient, 
c) private insurers, 
d) research funding, 
e) other. 
7. Who pays for IHC for MMR protein testing in your
practice? (tick one or more) 
a) the public health system, 
b) the patient, 
c) private insurers, 
d) research funding, 
e) other. 
Respectively, for MSI and IHC testing, 13 and 12
centres reported public funding only, and one British centre
reported public and private insurance funding. Three
centres (two in the US) reported support from research
sources. One centre did not answer and one did not test. 
D. Mutational analysis
1. Does your clinic ever proceed to mutational analysis
before provision of information from IHC as to
which MMR gene is involved? 
All but two centres are prepared to do mutation
analysis before provision of information from IHC
as to which MMR gene is involved, usually in
Amsterdam positive families. One UK centre did not
respond. 
2. What is the common mutational analytic strategy
adopted by your supporting laboratory? 
a) direct sequencing, 
b) PTT, 
c) PTT followed by deletion studies, 
d) other. 
The majority of centres did direct sequencing. Some
centres do deletion studies, all by MLPA (multiplex
ligation dependent probe amplification). Alternative
primary analysis was dHPLC (denaturing High
Performance Liquid Chromotography) by five centres
and PTT (Protein Truncation Test) by two centres. One
centre had no funding, and one British centre did not
answer the question. 
3. On which MMR genes do you regularly receive
mutational analytic results? 
Eight centres test for MLH1 and MSH2, and nine
centres test in addition MSH6. One centre had no
funding for testing. 
4. How does your clinic handle variants with no known
pathogenicity, e.g. no truncation on PTT? 
5. Is the family informed of such a finding? 
No centres used the finding of variants with no
known pathogenicity for predictive purposes. Approaches
varied as to use of this information: some used the data
for segregation analysis for research purposes, others
explored families and the variant information with IHC,
MSI, linkage analysis, and functional assays, checking
against the ICG HNPCC (now InSiGHT) database and
for positioning of conserved sites across species, and
amino acid change. Eleven centres discussed results of
variant polymorphisms with patients, and the remainder
did not answer. 
6. Who pays for initial mutational analysis in your
practice? (tick one or more) 
a) the public health system, 
b) the patient, 
c) private insurers, 
d) research funding, 
e) other. 
All except three centres receive public funding. One
has no funding as public payment has been withdrawn.
The USA centres receive payments from alternative
sources of patient, private insurers and research. One
British centre receives additional research funding, and
one centre receives private insurer's payments. 
7. Who pays for predictive DNA testing in your
practice? (tick one or more) 
a) the public health system, 
b) the patient, 
c) private insurers, 
d) research funding, 
e) other. 
All except the two USA centres receive public
funding. The USA centres rely on payment from the
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patient and private insurers and research. One British
centre also receives additional funding from private
insurer's payments. 
E. Counselling
1. Once a family-specific pathogenic mutation is
identified, do you advise family members of the
availability of a predictive test: 
a) Only through the counselled proband whose
DNA was tested? 
b) By direct mail to at-risk family members identified
on your clinic pedigree if the proband has
consented to such contact with the family,
provided they are consented in your HNPCC
register or have attended the clinic? 
c) By direct mail to at-risk family members identified
on your clinic pedigree if the proband has
consented to such contact with the family with or
without registration or attendance at the clinic. 
d) As in c) but only through a responsible doctor if
identified. 
e) By some other process (please specify). 
Nine centres chose to advise family members of the
availability of a predictive test only through the counselled
proband whose DNA was tested. Three centres will in
addition mail to family members consented in their
HNPCC register or who have attended clinic with the
consent of the proband. One Australian clinic is moving
to include direct mail to at-risk family members with the
proband's consent even if the family has not registered
or attended the clinic. Two British centres prefer this
approach as well. One USA centre will give a letter to
the proband to send to family members or through
a family meeting. A Danish centre contacts at-risk family
members via the proband and mail to all family
members that attend the clinic or who have indicated
interest; relatives who can't be informed in this way are
sent a standard letter from the national HNPCC Registry
provided the proband has consented. 
2. What would you do if an individual with an HNPCC
mutation declined to pass this information to other
family members at 50% risk of having inherited the
mutation and whose surveillance measures were
unknown/uncertain? 
a) respect his/her wishes, 
b) contact the at-risk individuals if possible, 
c) other. 
Seven centres would respect the proband's wishes.
Five centres would try very hard to persuade the
proband. One US centre would seek advice from its
ethics committee. One Australian centre would try to
persuade the proband to review the case with the
ethics committee before direct contact with the
relative. In one British centre, consent forms cover
dissemination of information to others; the proband
needs to specify up front if they don't want information
to be shared with at-risk family members. Three British
and one continental centre would contact the at-risk
individuals if possible. 
F. Surveillance planning
1. In your familial bowel cancer practice, for the purposes
of surveillance planning recommendations for
HNPCC, which definition of HNPCC do you accept? 
a) Amsterdam I, 
b) Amsterdam II, 
c) As per definition defined in A in my response, 
d) Other (please specify any variation). 
Ten centres offer HNPCC surveillance to Amsterdam
I and II family members. The remainder offer HNPCC
surveillance to families that they included in their
extended definitions as per question 1. 
2. Do you require molecular support (MSI testing, IHC
of MMR protein loss or genotyping) for the HNPCC
diagnosis before recommending surveillance
protocols appropriate for HNPCC? 
All centres responded no if Amsterdam criteria are met. 
3. Do you recommend surveillance planning for
HNPCC based on family history alone where
a) molecular pre-genetic or mutational testing is
negative (MSI stable/IHC present), 
b) molecular pre-genetic testing is not possible, 
c) mutation testing is negative, 
d) mutation testing is not possible, 
e) comment on other scenarios. 
Centres varied in their responses to this question.
All would advise surveillance on family history alone
but qualifications were varied. Fourteen still advised
HNPCC surveillance protocols even where mutational
analysis was not informative, or not possible. 
4. Do you recommend HNPCC surveillance protocols
where there is genetic information supporting the
diagnosis but no Amsterdam pedigree: 
a) with germline mutation in family, 
b) with MSI or immunohistochemistry support, but
no Amsterdam, 
c) other … comment. 
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All centres advise HNPCC surveillance regardless
of pedigree criteria where a MMC mutation is present.
Two additional centres accept MSI/IHC support even
without Amsterdam criteria or germline mutations for
the purposes of defining HNPCC surveillance protocol. 
5. What frequency do you recommend surveillance
colonoscopy in HNPCC? 
a) annual, 
b) every 2 years, 
c) every 3 years, 
d) other. 
Six centres advise annual colonoscopies in gene
carriers; one additional centre advises annual
colonoscopies in gene carriers only if that person is
affected. Ten centres advise biennial colonoscopic
surveillance. One US centre has specific frequency
criteria depending on colonoscopy findings. 
6. At what age do you recommend starting? 
Most centres recommend starting at age 25. 
7. What type of surveillance do you recommend for
endometrial and ovarian cancer in HNPCC?
Answers to this question were individualised across
clinics ranging from none except as part of a trial,
to only when symptomatic or where there is
endometrial cancer in the family, through to routine
annual endometrial biopsy, transvaginal ultrasound
and CA 125 testing. Twelve centres do advise TVUS
screening and seven advise CA 125 testing,
sometimes with certain caveats (postmenopausal
only, variable frequency). Starting ages varied from
25 to 35 where surveillance is planned. 
8. Is this gynaecological screening recommended to
females who are
a) gene carriers only, 
b) family members affected with syndrome-associated
cancers, 
c) first-degree relatives of gene carriers (of unknown
status), 
d) first-degree relatives of family members with
syndrome-associated cancers, 
e) second-degree relatives of gene carriers, 
f) second-degree relatives of family members with
syndrome-associated cancers, 
g) other recommendations. 
Nine centres offered gynaecological surveillance to
gene carriers, one exclusively. Three others offered
surveillance only to family members affected with
syndrome-associated cancers regardless of gene status.
Two appeared to restrict gynaecological surveillance to
first-degree relatives of affected members, presumably
considering the first tumour (usually colorectal) may
limit survival. Five others use this as one of several
indications, thus having broad indications for
surveillance. Eight centres recommend surveillance to
first-degree relatives of syndrome-affected patients
where that relative is not gene tested. Two centres
extended surveillance to second-degree relatives of
unknown gene status (one MSH6 only). 
9. What frequency do you recommend gynaecological
surveillance? 
a) annual, 
b) every 2 years, 
c) every 3 years, 
d) other. 
Twelve centres recommend gynaecological
surveillance annually. One British centre and two
European centres recommend a surveillance frequency
of every two years. Another three centres have no
recommendations for surveillance. 
10. At what age do you recommend starting
gynaecological surveillance? 
Commencing age for gynaecological screening
was nominated as more than 20 years (1 centre),
25 years (6 centres), 30 years (5 centres), 35 years
(3 centres). Three centres do not recommend
gynaecological surveillance. 
11. Do you use positive pre-genetic testing information
(where there is no germline mutation identified at
that time) to influence your surveillance planning?
If so, in what way? 
a) To increase frequency of colonoscopy, 
b) To advise gynaecological screening, 
c) To extend surveillance advice to beyond
first-degree relatives of affected members, 
a) In some other way (please specify). 
This question attracted less complete responses. Six
centres use MSI/IHC to influence frequency of
colonoscopy, three use this information to recommend
gynaecological surveillance across families and four
to advise surveillance to second- (or more) degree
relatives. Two indicated that this information did not
influence surveillance planning. 
12. In HNPCC, do you advise colonoscopic surveillance
for second-degree relatives of affected persons
where no mutation is identified in the family? If so,
starting at what age, and at what frequency? 
Elizabeth Chow et al
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Ten centres do screen second-degree relatives.
Routine screening is two yearly at one Australian
centre, whereas another Australian centre
recommends five yearly. Some centres' decisions
to screen are influenced by factors such as
pedigree characteristics (e.g. age of intervening
relative). Seven centres do not advise surveillance
for second-degree relatives. 
13. Does your clinic advise surveillance for non-colo-
rectal, extra-gynaecological sites in HNPCC
a) routinely. If yes, which ones? 
b) only if the pedigree indicates a specific target site
in one or more individuals, 
c) only if the pedigree indicates a specific target site
in more than one individual, 
d) based on specific MMR gene involved, 
e) based on other criteria (please specify). 
14. If you screen for extra-colonic, extra-gynaecological
cancers, please specify how often and by what means. 
15. Is this extra-colonic, extra-gynaecological screening
restricted to
a) gene carriers, 
b) members affected with a syndrome-associated
cancer, 
c) members affected with a syndrome-associated
cancer or colorectal adenoma, 
d) any of the above plus first-degree relatives, 
e) any of the above plus any relatives, 
f) any other scenario. 
Two centres routinely screen for non-colorectal,
non-gynaecological cancers (urinary tract and physical
examination). Twelve others recommend screening if
there is at least one of the target cancers in the
pedigree, whereas three others advise surveillance only
with two or more target sites affected in the family. Two
use the genotype (e.g. MSH2 families only) to inform
the decision. Where advised, surveillance strategies
varied: annual or biennial gastroscopy with Helicobacter
Pylori eradication, annual or biennial urine cytology and
abdominal ultrasound. Commencing age was variable.
Such screening was restricted to gene carriers only (2
centres); gene carriers or syndrome-affected family
members and their first-degree relatives (11 centres);
syndrome-affected family members only (3 centres). 
G. Surgery
1. Do you include discussion of prophylactic colonic
surgery in your counselling of gene carriers? 
Responses were evenly split: nine centres do and nine
centres do not include discussion of prophylactic
colonic surgery in counselling of gene carriers. 
2. Do you include discussion of prophylactic colonic
surgery in your counselling of individuals with
non-colonic syndrome-associated cancers in HNPCC
families with no mutation identified? 
Three British centres do offer discussions of prophylactic
colonic surgery in counselling of individuals with
non-colonic syndrome-associated cancers in HNPCC
families with no mutation identified. The rest of the
centres do not offer the discussion. 
3. Do you include discussion of prophylactic
gynaecological surgery in your counselling of gene
carriers? 
a) Premenopausally? 
b) Postmenopausally? 
c) After reproduction plans have been completed? 
4. Do you include discussion of prophylactic
gynaecological surgery in your counselling of individuals
with non-gynaecological syndrome-associated cancers
in HNPCC families with no mutation identified? 
a) Premenopausally? 
b) Postmenopausally? 
c) After reproduction plans have been completed? 
16 centres discussed prophylactic gynaecological
surgery for gene carriers including 10 in premenopausal
women and 14 after reproductive plans are complete.
Two centres do not, but one would use gene test postivity
to support other clinical indications for gynaecological
surgery. Seven centres would not counsel on
gynaecological surgery in syndrome-affected family
members with no mutation identified in the family, and
ten would do so (three for pre- and postmenopausal,
seven postmenopausal or after family plans complete). 
5. If surgery is indicated for a colonic cancer in
HNPCC, do you recommend
a) colectomy with ileorectal anastomosis, 
b) colectomy with ileo-sigmoid anastomosis, 
c) restorative proctocolectomy with ileo-anal pouch
anastomosis, 
d) restorative proctocolectomy with ileo-anal pouch
anastomosis only if there is a rectal cancer, 
e) conventional oncological surgery (left hemico-
lectomy, right hemicolectomy, anterior resection,
etc), 
f) no definite recommendation as evidence is
inadequate to decide, 
g) other surgical strategies (please specify). 
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6. Will a positive MSI result or IHC test showing loss
of MMR protein expression influence your surgical
approach or recommendation to that individual
a) only in the context of a family pedigree with
HNPCC, 
b) in any case, 
c) only in young patients (<50), 
d) no. 
Eight centres recommend colectomy with IRA and
two recommend restorative proctocolectomy with ileo-
anal pouch anastomosis (universally in one centre and
if rectal cancer present in another). One British centre
recommended extended hemicolectomy, and one
European centre a hemicolectomy. Three centres did
not use this information to influence surgical planning,
although one would consult surgeons informed with
this data. None of the centres recommended
conventional oncological surgery, but six centres left
the decision to surgical colleagues as evidence is
inadequate. MSI or IHC testing was influential in
surgical planning recommendations where in the
context of an HNPCC pedigree (10 centres), or in
patients under 50 years of age (5 centres) or in any
case (3 centres). In one of the latter, the respondent
commented that the finding of loss of MLH1 or low
level microsatellite instability might influence the
surgical approach, except where the promoter region
has not been analysed for its methylation status. 
Discussion
This survey conducted from September 2003 to
January 2004 was designed to highlight common
counselling and management questions relating to
HNPCC, especially where the evidence base for
decision making is poor or non-existent. Limitations to
the survey are recognised: continental Europe,
especially outside Denmark, and the USA are not well
represented. There were also no responses from Africa,
Asia, Japan or South America. Nevertheless, the
responding centres do represent clinics whose opinions
are influential in InSiGHT and the HNPCC community. 
Of interest was the wide variety of cancers
potentially included in the definition of HNPCC which
would inform a decision to proceed directly to
mutational analysis. Direct testing without IHC or MSI
for families where Amsterdam I or II criteria have been
met was common. Most centres also accept other
cancers for which there have been statistical
associations made of increased prevalence in HNPCC
[2, 4-10]. Five centres even accepted breast cancer in
hMLH families as relevant in this context [1]. 
Clinic intake threshold criteria probably relate more
to the provision of adequate funding and other
(human) resources than scientific scrutiny. In general,
thresholds were lower in “user pay” medical models,
and more restricted in other settings. 
Strategies of use of IHC and MSI were generally to
offer both. As more recent data are emerging, this
practice is probably changing due to the high
concordance between the two tests and the “added
value” of specific gene identification provided by IHC.
We suspect that clinics currently are moving to using
IHC as their main form of testing, with MSI reserved for
special circumstances. 
Consent for pre-genetic testing is a controversial area
of counselling practice. Some would say that the finding
of loss of expression of a mismatch repair gene (especially
MSH2) is tantamount to a germline diagnosis, and so
all the elements of counselling that go into consent for
germline testing should precede a request for IHC.
Others would propose that IHC and MSI are somatic
phenomena and conceptually little different to any other
phenotypic marker available for histopathological
characterisation; indeed they would argue that the
pathologist is duty bound to provide such information to
inform clinical practice for that patient. This argument is
increasingly supported by data that differentiate responses
to chemotherapy based on MSI status [11, 12], and
similarly the risk of metachronous cancer. Finally,
advocates of routine IHC testing, perhaps age restricted,
point out that this will be the best strategy to identify all
HNPCC families in the community for appropriate
counselling and surveillance. We suspect that standards
of consent for IHC and MSI testing are also changing in
different locations, pressured by forces protecting privacy
versus public good to differing degrees, depending on
local sociological and legal influences. 
The place of the Bethesda criteria in deciding on
pre-genetic testing has been the subject of two consensus
round table meetings [13, 14]. Our questionnaire was
completed before the most recent revisions were
published in Febuary 2004 [14]. This consensus has
rendered the criteria less specific. Nevertheless, it was
interesting to see the distribution of approach to these
criteria: nine restricted testing to Bethesda indications,
three were less restrictive but two were more restrictive.
It will be interesting to see how the 2004 conference
criteria play out in current clinical practice. We suspect
that their lack of specificity will make them unworkable. 
Most centres in this survey reported that their
pre-genetic, mutational analyses and predictive testing
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laboratory services were publicly funded. Notable
exceptions to this observation are centres from the USA.
Although comment on this is beyond the scope of this
article, lack of public funding must influence the impact
that familial counselling can have across families in
the community who have variable socio-economic
status and capacity to pay. 
The DNA mutational analysis strategies were quite
variable across centres. The variability partly reflects
the (rapid) developmental state of technology in this
discipline. It also offers opportunity for systematic
comparison of the efficiency of different strategies,
stratified on clinical (e.g. Bethesda) entry criteria, to be
evaluated. Cost effectiveness studies could follow. 
Disclosure of information about family specific
mutations in hereditary bowel cancer generally follows
the conventional clinical genetics model, leaving the
responsibility to probands with mutations identified.
Variations on this theme include providing letters to the
probands to facilitate accurate information transfer. The
success of this policy is under scrutiny in several centres,
with some clinics moving to directly inform at-risk
individuals known by the clinic to be at genetic risk. One
study shows a high level of communication failure to all
at-risk family members, despite genetic counselling (11
of 12 patients) [15]. Our own experience has been of
young family members developing advanced bowel
cancer after distant family counselling which has included
the need to inform other family members. Genetic
counselling and modes of disclosure have been bound
down in many countries by privacy considerations, often
enshrined in law. We consider that in the case of FAP at
least with its 100% penetrance for polyposis and cancer
and a clearly remedial strategy available to intercept the
cancer risk, privacy considerations have transgressed
common sense at the expense of the public good. 
Surveillance recommendations were more consistent
across the centres worldwide. There was some variation
related to intrinsic differences in the definition of HNPCC
(see above). Most centres will advise screening based on
family history regardless of genetic information (except in
individuals testing negative in families with a known
mutation). Non-informative mutational analysis or positive
results of pre-genetic testing were in general not
determinants of surveillance planning in themselves. On
the other hand, if a germline mutation is found, HNPCC
surveillance is recommended for carriers regardless of
family history. Frequency of screening is generally consistent
at one to two yearly. Gynaecological surveillance advice
was highly variable, probably reflecting the lack of
evidence for benefit and the lower incidence of
gynaecological cancers compared with colorectal cancers.
Starting ages of surveillance also varied. The categories
of people offered surveillance also varied considerably
across the centres. There is room for a randomised
controlled trial of gynaecological surveillance in HNPCC
registries to help address these uncertainties. 
Of considerable topical interest were surveillance
recommendations for non-colorectal, non-gynaecological
sites. The issue often arises in clinical practice. There is
no evidence base for these recommendations as the
frequency is too low to allow clinical studies. An audit of
outcomes from use of a standard protocol could be
considered through international cooperation. 
Surgical prophylaxis for gynaecological sites was
discussed in most centres, reflecting likely uncertainty
about the benefits of gynaecological surveillance and
the relative lack of function of the endometrium and, to
a lesser extent, ovaries after child bearing is complete. 
Almost all centres recommended extended colonic
surgery as the primary surgical approach in HNPCC.
This survey did not have responses from French centres
where such advice is less favoured [16]. Indeed, in the
absence of evidence, there is currently a German-
initiated randomised controlled trial of extended versus
oncological resection recruiting in Europe. The success
of surveillance by colonoscopy after a more limited
(oncological) resection will blunt the benefit (of preventing
metachronous tumours) afforded by extended surgery. 
Conclusion
The survey conducted in the last three months of
2003 has provided unique information about the clinical
practices and recommendations of eighteen familial
cancer clinics around the world. The questionnaire
covered clinical definition of HNPCC, clinical intakes,
indications and funding for pre-genetic testing and
mutational analysis, counselling, surveillance planning,
and surgical decision making. Newer information, which
may have influenced contemporary practice, has also
been discussed. The field of cancer genetics is advancing
quickly; therefore readers should be cognisant of the
time window of these responses. We consider this paper
to be a valuable and systematic catalogue of difficult but
common issues in familial cancer clinics, which can act
as a sounding board for practitioners in HNPCC. 
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